Precision Medicine and Genomics in Oncology
Session Overview
Precision medicine, anchored by comprehensive genomic profiling, has redefined cancer classification and therapeutic decision-making. This paradigm integrates tumor and germline genetics, epigenetics, and transcriptomics to identify actionable drivers, prognosticate outcomes, and reveal mechanisms of resistance. This session brings together molecular pathologists, bioinformaticians, clinical oncologists, and translational scientists to examine how genomic data is generated, interpreted, and ultimately applied at the point of care to personalize cancer management.
Why This Session Matters Now
Genomic testing has moved from the research bench to the standard-of-care for many cancers, creating both unprecedented opportunities and complex new challenges. The clinical translation of massive multi-omics datasets requires robust bioinformatics, clear biomarker-drug co-development, and frameworks for handling variants of unknown significance. Furthermore, the integration of liquid biopsy for dynamic monitoring and the need to identify hereditary risk are reshaping clinical pathways. This session addresses the critical transition from data generation to responsible clinical implementation, focusing on evidence-based practice, equitable access, and ethical considerations.
Key Scientific and Clinical Themes
Tumor Genomics, Epigenomics, and Multi-Omics Profiling
Examination of whole-genome, whole-exome, and transcriptomic sequencing applications in oncology, the role of epigenomic modifications, and integrative approaches to define molecular subtypes and uncover novel therapeutic vulnerabilities.
Biomarker Discovery and Companion Diagnostics
Analysis of the pathway from biomarker discovery through analytical and clinical validation to the development of regulated companion diagnostics essential for matching targeted therapies to eligible patient populations.
Pharmacogenomics and Therapy Selection
Focus on the use of genomic data to predict drug response, efficacy, and risk of severe toxicity, enabling truly personalized dosing and treatment choices beyond somatic tumor profiling.
Liquid Biopsy and Circulating Tumor DNA Applications
Discussion of the evolving utility of ctDNA analysis for minimal residual disease detection, early relapse monitoring, profiling tumor heterogeneity, and tracking clonal evolution in response to therapy.
Hereditary Cancer Syndromes and Risk Stratification
Exploration of germline genetic testing guidelines, the management of patients with pathogenic variants (e.g., in BRCA, Lynch syndrome genes), and the implications for cancer prevention, screening, and therapeutic targeting (e.g., PARP inhibitors).
Translational Genomics and Clinical Implementation Challenges
Critical appraisal of the real-world barriers to precision oncology, including tissue acquisition, turnaround time, cost, reimbursement, interpreting complex reports, and integrating genomic data into multidisciplinary tumor boards.
Nature of Research in This Field
Research in oncology genomics is characterized by large-scale collaborative consortia (e.g., TCGA, ICGC), rapid technological iteration in sequencing platforms, and a strong emphasis on clinical correlative studies. The literature is dominated by efforts to synthesize and review the ever-expanding genomic landscape of cancers to guide clinicians. Significant research investment is directed toward standardizing bioinformatic pipelines, validating liquid biopsy assays, and conducting health economics outcomes research to demonstrate the value of genomic testing.
Who Should Attend
This session is designed for:
- Medical oncologists, clinical geneticists, and molecular pathologists
- Translational researchers, bioinformaticians, and data scientists
- Laboratory directors and professionals in molecular diagnostics
- Clinical trialists involved in biomarker-stratified studies
- Fellows and trainees in oncology and cancer genomics
Session Perspective
A genomic report is not a prescription; it is a complex data set that requires sophisticated interpretation within a specific clinical context. This session provides a platform to bridge the gap between the capacity to sequence and the imperative to act wisely on the information. By focusing on the entire pipeline—from assay selection and bioinformatics to clinical decision-making and ethical disclosure—the discussion aims to advance a more mature, effective, and equitable model for precision oncology that delivers on its promise to improve patient outcomes.
If your research aligns with this session, we invite you to submit an abstract for consideration.
